NUTXNasdaqServices-Business Services, NECFiscal year ends December 31
Nutex Health Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$191.25+5.15 (+2.77%)
Close on Oct 19, 2026
- Market cap
- $1.34B
- P/E (TTM)
- 7.5
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
50.8%−6.8 pts over 5 years
Operating margin
31.5%−24.4 pts over 5 years
Net margin
8.1%−30.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +82.4% | +58.6% | +26.1% | +112.1% | |
| Gross profit | +126.4% | +206.6% | +23.0% | +98.5% | |
| Operating income | +110.9% | – | +12.5% | – | |
| Net income | +35.9% | – | -7.8% | +96.2% | |
| EPS, diluted | +8.2% | – | -17.2% | – | |
| Free cash flow | +1078.0% | +89.7% | +57.3% | +135.6% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 345.0% | 29247.7% | 30.7% | |
| Return on assets | -182.4% | 3088.4% | 9.0% | |
| Current ratio | 0.08 | 0.14 | 3.41 | |
| Debt to equity | – | -0.13 | 0.13 | |
| Net debt to EBITDA | – | -0.16× | -0.48× | |
| Interest coverage | -173.9× | 23.8× | 12.4× | |
| Inventory turnover | – | 8627.8× | 150.8× | |
| Capex to revenue | – | 22.3% | 0.3% | |
| Diluted shares | 0M | 1M | 7M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Nutex Health generated $496.57M from operations and spent $70.89M on capital expenditure, dividends and share buybacks. 93% of that went back into the business.
Generated
$496.57M
Used
$70.89M
Capital expenditure$65.89M93%Dividends$00%Share buybacks$5.00M7%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin8.1%
×Asset turnover1.11×
×Equity multiplier3.41×
=Return on equity, FY202530.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 8.1% | 1.11× | 3.41× | 30.7% |
| FY2024 | 10.9% | 0.91× | 5.43× | 53.7% |
| FY2023 | -18.5% | 0.60× | 5.28× | -58.2% |
| FY2022 | -193.7% | 0.53× | 3.93× | -403.6% |
| FY2021 | 40.0% | 1.68× | 3.48× | 233.6% |
| FY2020 | 38.7% | 79.86× | 9.47× | 29247.7% |
| FY2019 | -520.8% | 0.38× | 19.78× | -3941.8% |
| FY2018 | -69.5% | 0.72× | -1.51× | 76.2% |
| FY2017 | 2512.6% | 0.01× | -0.56× | -17.0% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
7of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$70.79M
- Cash generatingOperating cash flow above zero$248.13M
- Return on assets improvedROA up on the prior year13.1% → 10.8%
- Earnings backed by cashOperating cash flow above net income$248.13M vs $70.79M
- Less leverageLong-term debt to assets fell3.4% → 3.2%
- Better liquidityCurrent ratio rose1.90 → 3.41
- No dilutionShare count did not rise5M → 7M
- Gross margin improvedGross margin up on the prior year40.89% → 50.76%
- More efficientAsset turnover rose1.21 → 1.34